Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lipocine (LPCN) EBITDA (2016 - 2025)

Historic EBITDA for Lipocine (LPCN) over the last 13 years, with Q3 2025 value amounting to -$3.2 million.

  • Lipocine's EBITDA fell 4464.46% to -$3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$5.5 million, marking a year-over-year decrease of 3593.86%. This contributed to the annual value of $10231.0 for FY2024, which is 10006.27% up from last year.
  • Lipocine's EBITDA amounted to -$3.2 million in Q3 2025, which was down 4464.46% from -$2.2 million recorded in Q2 2025.
  • Lipocine's 5-year EBITDA high stood at $12.6 million for Q4 2021, and its period low was -$6.8 million during Q2 2021.
  • Its 5-year average for EBITDA is -$1.8 million, with a median of -$2.6 million in 2022.
  • In the last 5 years, Lipocine's EBITDA soared by 37947.96% in 2021 and then crashed by 17693.16% in 2023.
  • Over the past 5 years, Lipocine's EBITDA (Quarter) stood at $12.6 million in 2021, then tumbled by 117.24% to -$2.2 million in 2022, then decreased by 4.01% to -$2.3 million in 2023, then soared by 178.8% to $1.8 million in 2024, then plummeted by 278.57% to -$3.2 million in 2025.
  • Its EBITDA was -$3.2 million in Q3 2025, compared to -$2.2 million in Q2 2025 and -$1.9 million in Q1 2025.